On June 2, the inaugural meeting of thePharma-Derma-Alliance (PhDA) and the first Dermatology New Drug Clinical Research Summit Forum were held in Beijing; the alliance aims to strengthen synergistic innovation and scientific innovation in dermatology clinical research, new drug development and results transformation, and promote the linkage of "government, industry, academia, research and medicine", so as to promote the high-quality development and globalization of the dermatology innovative drug industry. The Alliance aims to promote the development and globalization of the dermatology innovative drug industry to benefit dermatology patients in China and around the world.
At present, the Alliance has accepted more than 50 directors and deputy directors of dermatology departments of major hospitals and leaders of clinical trial organizations, and 28 companies and investment institutions to join the Alliance; Zhang Jianzhong, director of the Department of Dermatology of the People's Hospital of Peking University, and Lu Qianjin, president of the Dermatology Hospital of the Chinese Academy of Medical Sciences, were elected as co-directors of thePharma-Derma-Alliance; and CEO Kevin Ding of E-nitiate Biopharmaceuticals was elected as vice chairman. At the same time, E-nitiate Biopharmaceuticals was elected as the vice chairman of the alliance.
On March 19, at the "China New Drug Summit Forum on New Drug Development and Innovation in Dermatology from a Global Perspective" hosted by China New Drug Journal, in order to promote the collaboration of innovative drug development in dermatology in China in an all-round and whole-chain manner, integrate the resources of academic organizations, medical institutions, pharmaceutical enterprises and related industry experts, and build an innovative drug development and academic exchange platform between industry, academia, research and application, the Beijing New Drug Consortium was established. In order to promote the collaboration of dermatology innovative drug development in China in a comprehensive and chain way, integrate resources from all walks of life, including academic organizations, medical institutions, pharmaceutical companies and related industry experts, and build a platform for innovative drug development and academic exchange, Zhang Jianzhong, director of the Department of Dermatology of Peking University People's Hospital, Lu Qianjin, president of the Dermatology Hospital of the Chinese Academy of Medical Sciences, Zheng Qingshan, professor of Shanghai University of Traditional Chinese Medicine, and Kevin Ding, CEO of Bio (Hangzhou) Co.
"In recent years, the national drug regulatory authorities have been pushing forward the reform of the drug review and approval system with unprecedented strength and speed, vigorously encouraging the research and development of innovative drugs, and China's pharmaceutical innovation has achieved a historic leap from running with to running alongside. In this context, thePharma-Derma-Alliance was established". Kong Fanpu, chief researcher of Tsinghua University and former director of the State Drug Administration Drug Review Center, pointed out in his speech at the inaugural meeting of thePharma-Derma-Alliance (PhDA) and the first Dermatology New Drug Clinical Research Summit.
"At a time when new dermatology drugs are developing rapidly in China, the establishment of thePharma-Derma-Alliance is very necessary." Alliance Co-Chairman Zhang Jianzhong said the alliance will give full play to the platform's five major roles, namely information exchange, academic services, resource aggregation, industry think tank and international leadership, thereby enhancing China's innovative research translation capabilities.
Facing the increasing demand for clinical drugs in dermatology, how to improve the level of research and development of innovative dermatology drugs and the level of translation of clinical results in China? At the Dermatology New Drug Clinical Research Summit held at the same time, Zhang Jianzhong and Lu Qianjin made keynote presentations on the current status of clinical research progress in dermatology in China, the current status of new drug development progress in dermatology in China, and the progress of new drug development for AhR targets at home and abroad. In addition, experts, scientists and entrepreneurs from the field of dermatology discussed in depth around the issues of clinical needs and new drug research and development.
Founded in 2020, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. is an innovative pharmaceutical company focused on innovative drugs for autoimmune diseases, developing breakthrough drugs through independent research and development paired with strategic collaborations, dedicated to solving the unmet needs of patients and improving the quality of human life.
The company is headquartered in Hangzhou, Zhejiang Province, and has a medical center and R&D center in Shanghai. The company is a key project introduced by Hangzhou Linping National Development Zone and won the first prize in the "2020 Hangzhou Overseas High-Level Talents Innovation and Entrepreneurship Competition (Life and Health Group)", and received tens of millions of RMB angel investment from the industrial capital Beida Fund. In 2022, the company has completed a series A financing of nearly 100 million yuan.
The company adheres to the value concept of "embracing competition, relentless pursuit, and forthright dedication", and has established a team of scientists with successful experience in new drug development from early stage PCC to clinical translation and clinical management. The company's globally patented Class I innovative drugs QY201， QY101，QY211 have been rapidly advanced to different clinical stages in different indications, and IND filings for multiple additional indications are imminent. By focusing on the unmet medical needs of patients, independently developing highly differentiated molecules, with streamline focus, the company strives to become a leader in the development of innovative drugs for autoimmune diseases.
